19Dec
As its COVID-19 Vaccine Nears Finalization, AstraZeneca Announces Deal to Buy Alexion for $39 Billion
AstraZeneca, the British-Swedish multinational pharmaceutical company currently collaborating with the University of Oxford on a COVID-19 vaccine, will purchase Alexion Pharmaceuticals for $39 billion. The transaction, which awaits approval by shareholders and regulators, is the largest purchase by a health care company this year and is expected to close in the third quarter of 2021. Alexion was founded in 1992 and is headquartered in Boston but has a global presence. It is known for its...
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
Locked-box pricing mechanisms in private merger and acquisition deals have been popular in recent ye...
Read More >
The impact of COVID-19, the ensuing delays and changes in the work, protecting the contractor’s cas...
Read More >
As the coronavirus rapidly spreads throughout America, some states, cities and counties have detaile...
Read More >
With the number of reported cases of coronavirus (COVID-19) increasing, the governors of Pennsylvani...
Read More >
The Confidentiality (or Non-Disclosure) Agreement (NDA) is the most maligned, and the most likely to...
Read More >
As the Coronavirus spreads on a worldwide level, employers have started to put into place certain me...
Read More >